Profit before payment of interest, taxes and amortization: Nautilus Bio (NAUT)
Nautilus Biotechnology is developing robotic AI laboratories, although financial stability currently depends on R&D investments. Operating cash flow before interest and taxes reflects profit dynamics, where 0.00 captures the current value of the indicator. High-throughput proteome mapping provides the company with immense market power due to the inelastic demand for protein analysis.
Nautilus Bio (NAUT) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- business book valuation details:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Nautilus Biotechnology|NAUT - Long-Term Debt to Capital|Short-Term Debt to Equity Nautilus Biotechnology, Inc.|NAUT - Company Aggregate Debts|Debts to Net Assets Nautilus Biotechnology|NAUT - Company Long-Term Debt|Short-Term Debt Nautilus Biotechnology|Intermediate Liquidity Ratio nautilus.bio
- business earnings and investment ratios data:
NAUT - Net Profit|Expected Net Profit Nautilus Biotechnology|NAUT - P/E Multiple|Projected Price to Earnings Nautilus Biotechnology, Inc.|NAUT - PEG Multiple|Business Value to Operating Income Before Depreciation Nautilus Biotechnology|NAUT - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Nautilus Biotechnology|NAUT - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months nautilus.bio|NAUT - Earnings per share growth in current year|Net earnings per share growth forecast for next year Nautilus Biotechnology
Summary company analytics:NAUT Nautilus Biotechnology
This indicator measures net cash flow from operating activities before depreciation and interest, allowing for an assessment of the business's internal efficiency regardless of debt load. By analyzing the EBITDA chronology, an investor can see how the liquidity of Nautilus Biotechnology (NAUT) depends on the adoption rates of proteomic platforms and the company's ability to convert scientific demand into actual operating income.
Competitors of Nautilus Biotechnology (NAUT)
Operating income before deduction of amortization Tempus (TEM)|QGEN - Profit before payment of interest, taxes and amortization|IONS: Profit before payment of interest, taxes and amortization|RGEN (Repligen) - Operating profit before deduction of amortization|Avidity Biosciences Inc (RNA) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization CRISPR Therapeutics Corp|GeneDx Corp (WGS) - Operating income before deduction of amortization|Operating profit before deduction of amortization RARE (Ultragenyx Pharmaceutical)|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta)|Twist Bioscience Inc - Profit before payment of interest, taxes and amortization|10x Genomics Corp - Operating profit EBITDA|Operating income before deduction of amortization Intellia Corp NTLA|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization biolifesolutions.com (BLFS)|Operating profit before deduction of amortization WVE|MAZE (Maze Therapeutics, Inc.) - Company profit before taxes, interest and amortization|Operating profit EBITDA SION|PRME - Profit before interest, taxes and amortization|Operating profit EBITDA TSHA (Taysha Gene Therapies)|QURE - Operating profit before deduction of amortization|MeiraGTx - Operating profit EBITDA|Income before deduction of interest, taxes and amortization RGNX (REGENXBIO Inc)|Solid Bio (SLDB) - Profit before payment of interest, taxes and amortization|Operating profit before amortization OCGN|Profit before payment of interest, taxes and amortization Pacific Biosciences|Profit before interest, taxes and amortization benitec.com BNTC|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Profit before payment of interest, taxes and amortization RCKT (Rocket Pharma)|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Lexeo Therapeutics Inc. (LXEO) - Profit before interest, taxes and amortization|Korro Bio, Inc - Operating profit EBITDA|Operating profit before depreciation charges editasmedicine.com (EDIT)|SLN (Silence Therapeutics plc) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization ProQR Therapeutics (PRQR)|Profit before payment of interest, taxes and amortization Codexis Inc|Operating profit before amortization SGMO (Sangamo BioSciences)|Operating profit EBITDA MGX|Operating profit EBITDA precisionbiosciences.com (DTIL)|Generation Bio - Operating profit before deduction of amortization|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR: Operating profit before deduction of amortization|Imunon, Inc. - Company profit before taxes, interest and amortization|PHIO: Operating profit EBITDA|Operating profit before amortization MBIO|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|Operating profit EBITDA bluebird bio, Inc (BLUE)|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|OMGA: Operating profit before amortization|Singular Genomics - Operating profit EBITDA|RGLS - Operating profit EBITDA|SYRS (Syros) - Operating profit before deduction of amortization|Telesis Bio, Inc (TBIO) - Operating profit EBITDA|Operating profit before deduction of amortization TCON|UBX (unitybiotechnology.com) - Company profit before taxes, interest and amortization
